884 related articles for article (PubMed ID: 16083515)
21. The clinical benefits of rivastigmine may reflect its dual inhibitory mode of action: an hypothesis.
Bullock R
Int J Clin Pract; 2002 Apr; 56(3):206-14. PubMed ID: 12018828
[TBL] [Abstract][Full Text] [Related]
22. Kinetic analysis of the inhibition of human butyrylcholinesterase with cymserine.
Kamal MA; Al-Jafari AA; Yu QS; Greig NH
Biochim Biophys Acta; 2006 Feb; 1760(2):200-6. PubMed ID: 16309845
[TBL] [Abstract][Full Text] [Related]
23. Cholinesterase inhibitors modify the activity of intrinsic cardiac neurons.
Darvesh S; Arora RC; Martin E; Magee D; Hopkins DA; Armour JA
Exp Neurol; 2004 Aug; 188(2):461-70. PubMed ID: 15246845
[TBL] [Abstract][Full Text] [Related]
24. Dual inhibition of acetylcholinesterase and butyrylcholinesterase enzymes by allicin.
Kumar S
Indian J Pharmacol; 2015; 47(4):444-6. PubMed ID: 26288480
[TBL] [Abstract][Full Text] [Related]
25. Comparison of inhibitory activities of donepezil and other cholinesterase inhibitors on acetylcholinesterase and butyrylcholinesterase in vitro.
Ogura H; Kosasa T; Kuriya Y; Yamanishi Y
Methods Find Exp Clin Pharmacol; 2000 Oct; 22(8):609-13. PubMed ID: 11256231
[TBL] [Abstract][Full Text] [Related]
26. Advances in the treatment of Alzheimer's disease: benefits of dual cholinesterase inhibition.
Ballard CG
Eur Neurol; 2002; 47(1):64-70. PubMed ID: 11803198
[TBL] [Abstract][Full Text] [Related]
27. The interactions of azure B, a metabolite of methylene blue, with acetylcholinesterase and butyrylcholinesterase.
Petzer A; Harvey BH; Petzer JP
Toxicol Appl Pharmacol; 2014 Feb; 274(3):488-93. PubMed ID: 24161345
[TBL] [Abstract][Full Text] [Related]
28. In Silico Analysis of Green Tea Polyphenols as Inhibitors of AChE and BChE Enzymes in Alzheimer's Disease Treatment.
Ali B; Jamal QM; Shams S; Al-Wabel NA; Siddiqui MU; Alzohairy MA; Al Karaawi MA; Kesari KK; Mushtaq G; Kamal MA
CNS Neurol Disord Drug Targets; 2016; 15(5):624-8. PubMed ID: 26996169
[TBL] [Abstract][Full Text] [Related]
29. Rosmarinus officinalis L. leaf extract improves memory impairment and affects acetylcholinesterase and butyrylcholinesterase activities in rat brain.
Ozarowski M; Mikolajczak PL; Bogacz A; Gryszczynska A; Kujawska M; Jodynis-Liebert J; Piasecka A; Napieczynska H; Szulc M; Kujawski R; Bartkowiak-Wieczorek J; Cichocka J; Bobkiewicz-Kozlowska T; Czerny B; Mrozikiewicz PM
Fitoterapia; 2013 Dec; 91():261-271. PubMed ID: 24080468
[TBL] [Abstract][Full Text] [Related]
30. Cerebrospinal fluid levels of biomarkers and activity of acetylcholinesterase (AChE) and butyrylcholinesterase in AD patients before and after treatment with different AChE inhibitors.
Parnetti L; Amici S; Lanari A; Romani C; Antognelli C; Andreasen N; Minthon L; Davidsson P; Pottel H; Blennow K; Gallai V
Neurol Sci; 2002 Sep; 23 Suppl 2():S95-6. PubMed ID: 12548360
[TBL] [Abstract][Full Text] [Related]
31. Selective acetyl- and butyrylcholinesterase inhibitors reduce amyloid-β ex vivo activation of peripheral chemo-cytokines from Alzheimer's disease subjects: exploring the cholinergic anti-inflammatory pathway.
Reale M; Di Nicola M; Velluto L; D'Angelo C; Costantini E; Lahiri DK; Kamal MA; Yu QS; Greig NH
Curr Alzheimer Res; 2014; 11(6):608-22. PubMed ID: 24359497
[TBL] [Abstract][Full Text] [Related]
32. Screening of traditional European herbal medicines for acetylcholinesterase and butyrylcholinesterase inhibitory activity.
Wszelaki N; Kuciun A; Kiss AK
Acta Pharm; 2010 Mar; 60(1):119-28. PubMed ID: 20228046
[TBL] [Abstract][Full Text] [Related]
33. Effects of switching from an AChE inhibitor to a dual AChE-BuChE inhibitor in patients with Alzheimer's disease.
Bartorelli L; Giraldi C; Saccardo M; Cammarata S; Bottini G; Fasanaro AM; Trequattrini A;
Curr Med Res Opin; 2005 Nov; 21(11):1809-18. PubMed ID: 16307702
[TBL] [Abstract][Full Text] [Related]
34. A patent review of butyrylcholinesterase inhibitors and reactivators 2010-2017.
Andrisano V; Naldi M; De Simone A; Bartolini M
Expert Opin Ther Pat; 2018 Jun; 28(6):455-465. PubMed ID: 29757691
[TBL] [Abstract][Full Text] [Related]
35. Identification of hybrid cholinesterase forms consisting of acetyl- and butyrylcholinesterase subunits in human glioma.
García-Ayllón MS; Sáez-Valero J; Muñoz-Delgado E; Vidal CJ
Neuroscience; 2001; 107(2):199-208. PubMed ID: 11731094
[TBL] [Abstract][Full Text] [Related]
36. Executive dyscontrol in dementia, with emphasis on subcortical pathology and the role of butyrylcholinesterase.
Bullock R; Lane R
Curr Alzheimer Res; 2007 Jul; 4(3):277-93. PubMed ID: 17627485
[TBL] [Abstract][Full Text] [Related]
37. IN VITRO ACETYLCHOLINESTERASE AND BUTYRYLCHOLINESTERASE INHIBITORY POTENTIALS OF JATROPHA GOSSYPIFOLIA PLANT EXTRACTS.
Saleem H; Ahmad I; Shahid MN; Gill MS; Nadeem MF; Mahmood W; Rashid I
Acta Pol Pharm; 2016; 73(2):419-23. PubMed ID: 27180434
[TBL] [Abstract][Full Text] [Related]
38. The effect of heptyl-physostigmine, a new cholinesterase inhibitor, on the central cholinergic system of the rat.
De Sarno P; Pomponi M; Giacobini E; Tang XC; Williams E
Neurochem Res; 1989 Oct; 14(10):971-7. PubMed ID: 2608162
[TBL] [Abstract][Full Text] [Related]
39. Sustained cholinesterase inhibition in AD patients receiving rivastigmine for 12 months.
Darreh-Shori T; Almkvist O; Guan ZZ; Garlind A; Strandberg B; Svensson AL; Soreq H; Hellström-Lindahl E; Nordberg A
Neurology; 2002 Aug; 59(4):563-72. PubMed ID: 12196650
[TBL] [Abstract][Full Text] [Related]
40. Species- and concentration-dependent differences of acetyl- and butyrylcholinesterase sensitivity to physostigmine and neostigmine.
Bitzinger DI; Gruber M; Tümmler S; Michels B; Bundscherer A; Hopf S; Trabold B; Graf BM; Zausig YA
Neuropharmacology; 2016 Oct; 109():1-6. PubMed ID: 26772968
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
